Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

https://ift.tt/4izlXwW

from Sanofi - Aventis Groupe https://ift.tt/5Ve82K7
via IFTTT

Post a Comment

0 Comments